Rachel J. Archer
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
What US medical students need to learn about clinical practice guidelines: a qualitative study of US students and a global subset of guidelines developers.
Journal: Journal of clinical epidemiology
Published: September 24, 2025
Factors affecting the successful implementation of Global Polio Eradication Initiative (GPEI) in low- and middle-income countries.
Journal: Journal of global health
Published: April 11, 2020
Interventions to promote oral nutritional behaviours in people living with neurodegenerative disorders of the motor system: A systematic review.
Journal: Clinical nutrition (Edinburgh, Scotland)
Published: August 15, 2019
Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
Journal: International journal of technology assessment in health care
Published: February 07, 2019
Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.
Journal: Health technology assessment (Winchester, England)
Published: December 04, 2018
Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Journal: PharmacoEconomics
Published: May 28, 2017
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Journal: The Journal of rheumatology
Published: December 16, 2016
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England)
Published: December 07, 2016
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Journal: Health technology assessment (Winchester, England)
Published: May 26, 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England)
Published: May 04, 2016
A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
Journal: PharmacoEconomics
Published: April 30, 2016
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Journal: PharmacoEconomics
Published: October 19, 2015
Last Updated: 09/26/2026